Cabrini Hospital, Medical Oncology, Melbourne, Australia.
Peter MacCallum Cancer Centre, Medical Oncology, 305 Grattan St, Melbourne, VIC, 3000, Australia.
Support Care Cancer. 2018 Feb;26(2):483-489. doi: 10.1007/s00520-017-3852-z. Epub 2017 Aug 22.
Eyebrow and eyelash loss (madarosis) is a common and distressing side effect of chemotherapy for which no protective strategies have yet been developed. The purpose of this study was to develop an overview of perceptions and experiences of women undergoing taxane-based treatment for early breast cancer.
A total of 25 women with a diagnosis of invasive early breast cancer participated in a focus group (n = 5), ages ranging from 35 to 64 (median 50), all had completed therapy with a taxane-based chemotherapy treatment. This focus group used targeted questions to explore participants' perceptions and experience of madarosis during and following chemotherapy and identified issues associated with impact of madarosis on quality of life (QoL). Thematic analysis was conducted to identify important issues experienced by participants.
Seven themes emerged from the data: (1) timing of regrowth and permanent changes, (2) meaning/importance of eyebrow/eyelashes, (3) preparedness/information given, (4) impact of the hair loss of self, (5) impact of hair loss on others, (6) physiological side effects of loss of eyebrows/eyelashes, and (7) management of loss of eyebrows/eyelashes. In addition, participants noted physical symptoms of eye irritation during their treatment that they attributed to madarosis.
This study highlights the significant impact of madarosis on patients, providing the first published analysis of patient's attitude and perception of eyelash and eyebrow loss during chemotherapy. Further research in this area is required and will be benefitted from the development of a dedicated instrument/questionnaire that can capture and measure the impact of madarosis on QoL and allow development of clinical trial strategies.
眉毛和睫毛脱落(眉毛和睫毛缺失)是化疗的常见且令人痛苦的副作用,但目前尚无任何保护策略。本研究的目的是概述接受紫杉烷类药物治疗早期乳腺癌的女性对其的看法和经历。
共有 25 名患有浸润性早期乳腺癌的女性参与了焦点小组(n=5),年龄从 35 岁到 64 岁(中位数 50 岁),均已完成基于紫杉烷的化疗治疗。该焦点小组使用针对性问题探讨了参与者在化疗期间和之后对眉毛缺失的看法和体验,并确定了与眉毛缺失对生活质量(QoL)的影响相关的问题。使用主题分析来识别参与者经历的重要问题。
从数据中出现了七个主题:(1)再生和永久性变化的时间,(2)眉毛/睫毛的意义/重要性,(3)准备/提供的信息,(4)脱发对自身的影响,(5)脱发对他人的影响,(6)失去眉毛/睫毛的生理副作用,和(7)失去眉毛/睫毛的管理。此外,参与者注意到他们在治疗过程中眼睛刺激的身体症状,他们将这些症状归因于眉毛和睫毛缺失。
本研究强调了眉毛和睫毛缺失对患者的重大影响,首次发表了患者对化疗期间睫毛和眉毛缺失的态度和看法的分析。需要在这一领域进行进一步的研究,这将得益于专门的仪器/问卷的开发,该仪器/问卷可以捕捉和衡量眉毛和睫毛缺失对 QoL 的影响,并允许制定临床试验策略。